This inventor holds 1 USPTO granted patent. Top assignee: Amylin Pharmaceuticals, Inc.. Active years: 1997.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1997
Title: Lori Gaeta: Innovator in Amylin Antagonist Peptides
Introduction
Lori Gaeta is a prominent inventor based in Olivenhain, California. She has made significant contributions to the field of biochemistry, particularly in the development of peptides that target amylin activity. Her work is crucial for advancing treatments for various metabolic conditions.
Latest Patents
Lori Gaeta holds a patent for "Selective amylin antagonist peptides and uses therefor." This patent describes peptides that inhibit amylin activity while exhibiting selectivity for amylin receptors over calcitonin and CGRP receptors. These innovative peptides have potential applications in treating conditions such as Type 2 diabetes mellitus, impaired glucose tolerance, obesity, insulin resistance, and hypertension. She has 1 patent to her name.
Career Highlights
Lori Gaeta is associated with Amylin Pharmaceuticals, Inc., where she has been instrumental in research and development efforts. Her expertise in peptide design and function has positioned her as a key figure in the pharmaceutical industry.
Collaborations
Throughout her career, Lori has collaborated with notable colleagues, including Kevin Beaumont and Kathryn Susan Prickett. These partnerships have enhanced her research and contributed to the advancement of therapeutic solutions.
Conclusion
Lori Gaeta's innovative work in amylin antagonist peptides showcases her dedication to improving health outcomes for individuals with metabolic disorders. Her contributions continue to influence the field of biochemistry and pharmaceutical development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile